BY CHRIS BAKER, SENIOR VICE PRESIDENT AND GLOBAL HEAD OF FSP, PAREXEL & JOANNE SULLIVAN, GLOBAL HEAD OF SAFETY AND REGULATORY OUTSOURCING, PAREXEL & LISA FEENEY, VICE PRESIDENT, CLINICAL OPERATIONS FOR EXECUPHARM & YUN HARDIMAN, VICE PRESIDENT, BIOSTATISTICS FSP, PAREXEL – 7.17.20 – 6 min
In an already challenging clinical trial environment, the COVID-19 era has exacerbated uncertainty on an unprecedented scale. In a matter of days, biopharmaceutical companies faced the challenges of harnessing all available resources and expertise at warp speed to begin development of potential vaccines and treatments for COVID-19, while also keeping mission critical non-COVID trials moving.
Sorgente articolo:
UPDATED: In blow to anti-aging field, Unity Biotechnology fails first major study, cuts lead program – Endpoints News
| User ID | Campaign ID | Link |
|---|---|---|
| d9a95efa0a2845057476957a427b0499 | l-99999994 | Email Marketing |
| d9a95efa0a2845057476957a427b0499 | l-99999982 | Cloud Real Time |
| d9a95efa0a2845057476957a427b0499 | l-99999979 | Fiasconaro |
| d9a95efa0a2845057476957a427b0499 | l-99999984 | Cloud Real Time |